Q1 2025 Management View Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology ...

The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) ...

A Rochester man celebrated being five years cancer-free Thursday by walking around Mayo Clinic thanking the doctors that saved his life.

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

“Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer,” said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...

"Optune Lua is an innovative and urgently needed new approach for treating metastatic non-small cell lung cancer," said Joachim Aerts, M.D., a LUNAR investigator and Professor of Pulmonary ...